The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation.
 
Andrea B. Apolo
No Relationships to Disclose
 
Karla V. Ballman
Consulting or Advisory Role - Agenus; Takeda
Patents, Royalties, Other Intellectual Property - Prostate cancer signature patent (Inst)
Expert Testimony - Janssen Oncology; Mylan; Sanofi
 
Guru P. Sonpavde
Employment - Myriad Genetics (I)
Honoraria - UpToDate
Consulting or Advisory Role - Astellas Pharma; Bicycle Therapeutics; Bristol-Myers Squibb; EMD Serono; Exelixis; G1 Therapeutics; Genentech; Gilead Sciences; Infinity Pharmaceuticals; Janssen; Loxo/Lilly; Lucence; Merck; Pfizer; Scholar Rock; Seagen; Syapse; Vial
Speakers' Bureau - Exelixis; Gilead Sciences; INFORMAÇÃO BRASILEIRA DE ONCOLOGIA; Medscape; Natera; Onclive; Physicans' Education Resource; Research to Practice; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); GeneCentric (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Predicine (Inst); QED Therapeutics (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Other Relationship - Astellas Pharma; Bristol-Myers Squibb; Elsevier; G1 Therapeutics; Mereo BioPharma; QED Therapeutics
 
Stephanie A. Berg
Honoraria - Aptitude Health; MJH Life Sciences
Consulting or Advisory Role - Bristol Meyers Squibb; Genzyme; Myovant Sciences; Pfizer; Seattle Genetics/Astellas
Speakers' Bureau - Bristol-Myers Squibb/Celgene; Eisai; Exelixis
Travel, Accommodations, Expenses - Eisai; Exelixis
 
William Y. Kim
Employment - Focal Medical, Inc. (I)
Leadership - Focal Medical, Inc. (I)
Stock and Other Ownership Interests - Abbvie; Abbvie; Amgen; Apellis Pharmaceuticals; Arvinas; Arvinas; BeiGene; Bristol-Myers Squibb; Kura Oncology; Moderna Therapeutics; Natera; Oramed; Revolution Medicines; Tango Therapeutics; Zentalis
Research Funding - Foundation Medicine; GeneCentric; Merck
Patents, Royalties, Other Intellectual Property - BASE47 bladder cancer subtype classifier; PurIST (Purity Independent Subtyping of Tumors) (I)
Other Relationship - Merck
 
Rahul Atul Parikh
Stock and Other Ownership Interests - IBRX (I)
Patents, Royalties, Other Intellectual Property - Patents on DNA repair pathways in cancer. I do not receive any royalties for the same.
 
Min Yuen Teo
Consulting or Advisory Role - Janssen Oncology
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Pharmacyclics (Inst)
 
Randy F. Sweis
Stock and Other Ownership Interests - Abbvie (I)
Honoraria - AVEO; Exelixis
Consulting or Advisory Role - AstraZeneca/MedImmune; AVEO; Bristol-Myers Squibb; Eisai; Exelixis; Janssen Oncology; Mirati Therapeutics; Pfizer; Seattle Genetics/Astellas
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Ascendis Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Eisai (Inst); EpiVax Oncology (Inst); Genentech (Inst); Immunocore (Inst); Jounce Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pionyr (Inst); Pyxis (Inst); QED Therapeutics (Inst); Scholar Rock (Inst)
Patents, Royalties, Other Intellectual Property - Neoantigens in Cancer, PCT/US2020/031357
 
Daniel M. Geynisman
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Exelixis; Merck; Myovant Sciences; Pfizer; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); Calithera Biosciences (Inst); Genentech (Inst); Harpoon therapeutics (Inst); Merck (Inst)
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; AADi; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; BostonGene; Bristol-Myers Squibb; CG Oncology; Dyania Health; EMD Serono; Fresenius Kabi; G1 Therapeutics; Gilead Sciences; Guardant Health; ImmunityBio; Janssen; Lucence; Merck; Pfizer; PureTech; Roche; Seagen; Silverback Therapeutics; Strata Oncology; Urogen pharma
Research Funding - Acrivon Therapeutics (Inst); ALX Oncology (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Gurkamal S. Chatta
Consulting or Advisory Role - Cardinal Health
Research Funding - Abbvie (Inst); Taiho Oncology (Inst)
Travel, Accommodations, Expenses - Cardinal Health
 
Zachery R Reichert
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst)
 
Joseph W. Kim
Consulting or Advisory Role - Clovis Oncology; EMD Serono; Halda Therapeutics; Janssen Biotech; Janssen Oncology; Sanofi
Research Funding - ADC Therapeutics (Inst); Cosmo Pharmaceuticals; Dendreon (Inst); Exelixis (Inst); Hummingbird (Inst); IgM Biosciences (Inst); Janux Therapeutics (Inst); Regeneron (Inst); Roche (Inst)
 
Mehmet Asim Bilen
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; SeaGen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genome & Company (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
 
Bradley Alexander McGregor
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Genentech/Roche; Merck; Pfizer; Seattle Genetics/Astellas
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Pfizer/EMD Serono (Inst); Seattle Genetics/Astellas (Inst)
 
Sandy Srinivas
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Janssen Oncology; Merck; Novartis; Seagen
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Merck (Inst); Seattle Genetics/Astellas (Inst)
Other Relationship - Pfizer
 
Susan Halabi
Employment - ASCO
Consulting or Advisory Role - Aveo; Bristol-Myers Squibb; J&J; Sanofi
Research Funding - Astellas Pharma (Inst)
 
Gabriela Perez Burbano
No Relationships to Disclose
 
Michael J. Morris
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - Amgen; AstraZeneca; Blue Earth Diagnostics; Clarity Pharmaceuticals; Convergent Therapeutics; Daiichi; ITM Isotope Technologies Munich; Lantheus Medical Imaging; Pfizer; POINT Biopharma; Progenics; Telix Pharmaceuticals; Z-Alpha
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Janssen (Inst); Novartis (Inst); Progenics (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - APCCC; AstraZeneca; Memorial Sloan-Kettering Cancer Center
(OPTIONAL) Uncompensated Relationships - Bayer; Janssen Oncology; Novartis
 
Jonathan E. Rosenberg
Honoraria - Clinical Care Options; Medscape; MJH Life Sciences; NCCN/Pfizer; Peerview; Pfizer; Physicans' Education Resource; Research To Practice; UpToDate
Consulting or Advisory Role - Alligator Bioscience; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Century Therapeutics; Gilead Sciences; GlaxoSmithKline; Hengrui Pharmaceutical; Immunomedics; Imvax; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Pfizer/EMD Serono; QED Therapeutics; Roche/Genentech; Seagen; Tyra Biosciences
Research Funding - Acrivon Therapeutics; Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); QED Therapeutics (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)